Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience
Background Fingolimod (FTY) and dimethyl fumarate (DMF) are multiple sclerosis (MS) oral therapies that became available in 2010 and 2013, respectively. Objective The objective of this article is to compare discontinuation rates, efficacy, and adverse events (AEs) of FTY and DMF over two years. Meth...
Збережено в:
| Автори: | , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
SAGE Publishing
2017-08-01
|
| Серія: | Multiple Sclerosis Journal - Experimental, Translational and Clinical |
| Онлайн доступ: | https://doi.org/10.1177/2055217317725102 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|